Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 8, 2020

University of Oxford selects eClinical suite for Covid-19 trial

Unified eClinical solutions provider Axiom Real-Time Metrics has announced its partnership with the University of Oxford for its clinical trial focused on the preventative treatments of Covid-19.

Unified eClinical solutions provider Axiom Real-Time Metrics has announced its partnership with the University of Oxford for its clinical trial focused on the preventative treatments of Covid-19.

Named COPCOV, the trial is led by the University of Oxford-supported Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok.

It is designed to recruit 40,000 frontline healthcare workers and staff in Europe, Africa, Asia, and South America.

The study began in April this year. It will run for one year and is currently the ‘largest interventional trial’ being conducted at a global level.

Axiom’s eClinical suite Fusion will deliver tools required for electronic data collection and electronic patient-reported outcomes.

Axiom founder and CEO Andrew Schachter said: “We are honoured that the University of Oxford and its collaborators have placed their trust in Axiom with respect to the criticality of the of real-time capture of clinical daily patient reported outcomes to this study and the management of its trial data.”

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

“Over the past 20 years, Axiom has supported trials of global importance, and this study is no exception. Indeed, it is unprecedented in many aspects. Playing our part to enable this study is a point of pride for the entire Axiom global team.”

Fusion will also deliver randomisation and reporting functions for the study.

Mahidol Oxford Research Unit data management head Naomi Waithira said: “It’s been a pleasure working with the Axiom team as we rapidly configured this study in just a few weeks. I greatly appreciate their contributions to our research.”

In March this year, Researchers at the University of Oxford in the UK commenced enrolment of healthy volunteers for a clinical trial of the Covid-19 vaccine candidate ChAdOx1 nCoV-19.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU